Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Omeros Corporation (OMER)

3.86   0.17 (4.61%) 03-24 16:00
Open: 3.62 Pre. Close: 3.69
High: 3.88 Low: 3.51
Volume: 210,069 Market Cap: 243(M)

Technical analysis

as of: 2023-03-24 4:28:33 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 5.39     One year: 6.3
Support: Support1: 3.64    Support2: 3.04
Resistance: Resistance1: 4.61    Resistance2: 5.39
Pivot: 3.62
Moving Average: MA(5): 3.59     MA(20): 3.66
MA(100): 3.06     MA(250): 3.58
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 68.3     %D(3): 56.9
RSI: RSI(14): 53.3
52-week: High: 7.75  Low: 1.74
Average Vol(K): 3-Month: 950 (K)  10-Days: 330 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ OMER ] has closed below upper band by 19.1%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.88 - 3.89 3.89 - 3.91
Low: 3.47 - 3.49 3.49 - 3.5
Close: 3.83 - 3.86 3.86 - 3.88

Company Description

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Headline News

Fri, 17 Mar 2023
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt - Simply Wall St

Tue, 14 Mar 2023
Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript - Yahoo Finance

Mon, 13 Mar 2023
Omeros Corporation to Announce Fourth Quarter and Year End ... - Manchestertimes

Wed, 08 Feb 2023
Omeros (OMER): $200M Added To The Company's Balance Sheet ... - Seeking Alpha

Fri, 23 Dec 2022
How Will the Market React to Omeros Corporation (OMER) Stock Getting a Bullish Rating - InvestorsObserver

Wed, 09 Nov 2022
Omeros Corporation Reports Third Quarter 2022 Financial Results - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 63 (M)
Shares Float 60 (M)
% Held by Insiders 4 (%)
% Held by Institutions 32.5 (%)
Shares Short 8,520 (K)
Shares Short P.Month 8,610 (K)

Stock Financials

EPS -2.42
EPS Est Next Qtl -0.32
EPS Est This Year -1.3
EPS Est Next Year -0.7
Book Value (p.s.) -1.97
Profit Margin (%) 0
Operating Margin (%) 553.7
Return on Assets (ttm) -35.8
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share -0.48
EBITDA (p.s.) -2.64
Qtrly Earnings Growth 0
Operating Cash Flow -79 (M)
Levered Free Cash Flow -130 (M)

Stock Valuations

PE Ratio -1.6
PEG Ratio -0.1
Price to Book value -1.97
Price to Sales -8.08
Price to Cash Flow -3.06

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.